Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin flat dosing versus intra-patient dose escalation in ovarian, fallopian tube, and primary peritoneal cancers
ACTRN12605000694617Phase 3Completed
- Sponsor
- Scottish Gynaecological Cancer Trials Group
- Start
- Jan 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Scottish Gynaecological Cancer Trials Group. Primary endpoint: Progression-free survival. Started Jan 2006; status: completed.
02
Drugs
carboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12605000694617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000694617.